-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Collaborates with Nference for Cardiometabolic Research

MT Newswires·11/18/2026 05:57:44
Listen to the news
05:57 AM EST, 11/18/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) partnered with artificial intelligence-focused healthcare research company Nference to advance research in cardiometabolic diseases, including obesity, diabetes and cardiovascular disease. The Danish drugmaker will contribute its clinical trial data, which will be analyzed using Nference's AI platform, according to a Wednesday release. The partners plan to identify new research opportunities that could lead to the development of future treatments. The deal also includes a framework to explore potential new health-focused ventures for cardiometabolic health and healthy aging.